Recombinant human granulocyte-stimulating factor injection

This product is human granulocyte colony stimulating factor (rhG-CSF) produced by gene recombination technology. Compared with natural products, its biological activity is basically the same in vivo and in vitro. rhG-CSF is one of the main cytokines that regulate granulocyte hematopoiesis in the bone marrow. It selectively acts on granulocyte hematopoietic progenitor cells, promotes their proliferation and differentiation, and can increase the function of granulocyte terminal undifferentiated cells.

Recombinant human granulocyte colony-stimulating factor.

Colorless transparent liquid.

1. Neutropenia caused by cancer chemotherapy and other reasons; cancer patients use bone marrow suppressive chemotherapy drugs, especially after strong bone marrow deprivation chemotherapy drugs, injection of this product can help prevent the occurrence of neutropenia, reduce the degree of neutropenia, shorten the duration of agranulocytosis, accelerate the recovery of granulocyte count, and thus reduce the risk of concurrent infection and fever. 2. Promote the increase of neutrophil count after bone marrow transplantation. 3. Neutropenia caused by myelodysplastic syndrome, neutropenia caused by aplastic anemia, congenital and idiopathic neutropenia, myelodysplastic syndrome with neutropenia, and cyclical neutropenia.

This product should be injected subcutaneously or intravenously 24 to 48 hours after the end of chemotherapy, once a day. The dosage and duration of this product should be determined according to the intensity of the patient's chemotherapy and the degree of neutrophil decrease. For patients with high-intensity chemotherapy or more obvious neutrophil decrease, it is more appropriate to use it continuously for more than 7 days at a dose of 2.5μg/kg body weight/day, and stop the drug when the neutrophil count recovers to 5000/mm3; if the dose of chemotherapy drugs used is low and the bone marrow suppression is estimated to be not too severe, a lower dose can be considered to prevent neutropenia, and the dose of 1.25μg/kg body weight/day can be used until the neutrophil count stabilizes within a safe range. For patients whose neutrophil count has been significantly reduced after chemotherapy (neutrophil count <1000/mm3), 5μ

1. Musculoskeletal system: sometimes there will be muscle soreness, bone pain, back pain, chest pain. 2. Digestive system: sometimes there will be loss of appetite, or liver alanine aminotransferase and aspartate aminotransferase will increase. 3. Others: some people will have fever, headache, fatigue and rash, ALP and LDH will increase. 4. Very few people will experience shock, interstitial pneumonia, adult respiratory distress syndrome, and increase in immature cells.

1. Patients who are allergic to granulocyte colony stimulating factor and other preparations expressed by E. coli are contraindicated. 2. Patients with severe liver, kidney, heart, and lung dysfunction are contraindicated. 3. Myeloid leukemia patients whose immature granulocytes in the bone marrow have not decreased significantly or myeloid leukemia patients with immature granulocytes detected in peripheral blood.

Precautions for children: Use with caution in children and give appropriate monitoring; since the safety of the drug for newborns and infants has not been determined, it is recommended not to use the drug. No long-term toxic effects were found in patients aged 4 months to 17 years who took the drug daily, and their growth, development, sexual characteristics and endocrine system were not changed. Precautions for pregnancy and lactation: Safety during pregnancy has not been established. When it is proven that the potential benefits of the drug for pregnant women outweigh the potential risks to the fetus, it should be used. Lactating women should stop breastfeeding before taking the drug. Precautions for the elderly: The physiological functions of elderly patients are relatively low, so it is necessary to observe the patient's condition, pay attention to the dosage and interval, and administer the drug with caution. Its safety and effectiveness have not yet been established.

It is not completely clear. Drugs that promote the release of white blood cells (such as lithium) should be used with caution.

Store at 2～8℃ away from light

250μg/bottle

24 months

Beijing SL Pharmaceutical Co., Ltd.

• Founded in:

  1994-12-24

• Address:

  4th Floor, Building 1, Bitongyuan, No. 69, Fushi Road, Haidian District, Beijing

• Tax NO.:

  91110000102299779W

• Registered Funds:

  1,027.35 million yuan

• Website:

  Log in to view

• Email:

  Log in to view